1. Myostatin is a member of the transforming growth factor β superfamily of secreted growth factors that negatively regulates skeletal muscle size.
2.Mice null for the gene have increased muscle mass, reduced adiposity, increased insulin sensitivity, and resistance to obesity.
3.Myostatin inhibition in adult mice increases muscle mass, raising the possibility of anti-myostatin therapy for treating diseases such as obesity or diabetes in addition to muscle wasting diseases.
The article is generally reliable and trustworthy, as it provides evidence from scientific studies and research on the effects of the gene mutation on mice. The article also provides a detailed description of the potential benefits of inhibiting the gene in adult mice, which could be used to treat various diseases such as obesity or diabetes. However, there are some potential biases that should be noted. For example, the article does not explore any potential risks associated with inhibiting this gene in adult mice, nor does it present both sides equally when discussing its potential benefits. Additionally, there is no mention of any possible counterarguments or alternative treatments that could be used instead of inhibiting this gene in adult mice. Furthermore, there is no discussion about how this treatment would affect humans if it were to be used in clinical practice. Therefore, while this article is generally reliable and trustworthy, further research should be conducted to explore these issues before any conclusions can be drawn about its efficacy and safety for use in humans.